C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.

C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. Abstract Text:

Uma Singh,Sridevi Devaraj,Jeannette Vasquez-Vivar,Ishwarlal Jialal,Uma Singh,Sridevi Devaraj,Jeannette Vasquez-Vivar,Ishwarlal Jialal,Uma Singh,Sridevi Devaraj,Jeannette Vasquez-Vivar,Ishwarlal Jialal,

C-reactive protein (CRP), a cardiovascular risk marker, induces endothelial dysfunction. We have previously shown that CRP decreases endothelial nitric oxide synthase (eNOS) expression and bioactivity in human aortic endothelial cells (HAECs). In this study, we examined the mechanisms by which CRP decreases eNOS activity in HAECs. To this end, we explored different strategies such as availability of tetrahydrobiopterin (BH4)-a critical cofactor for eNOS, superoxide (O(2)(-)) production resulting in uncoupling of eNOS and phosphorylation/dephosphorylation of eNOS. CRP treatment significantly decreased levels of BH4 thereby promoting eNOS uncoupling. Pretreatment with sepiapterin, a BH4 precursor, prevented CRP-mediated effects on BH(4) levels, superoxide production as well as eNOS activity. The gene expression and enzymatic activity of GTPCH1, the first enzyme in the de novo biosynthesis of BH(4), were significantly inhibited by CRP. Importantly, GTPCH1 is known to be regulated by cAMP-mediated pathway. In the present study, CRP-mediated inhibition of GTPCH1 activity was reversed by pretreatment with cAMP analogues. Furthermore, CRP-induced O(2)(-) production was reversed by pharmacologic inhibition and siRNAs to p47 phox and p22 phox. Additionally, CRP treatment significantly decreased the eNOS dimer: monomer ratio confirming CRP-mediated eNOS uncoupling. The pretreatment of cells with NO synthase inhibitor (N-nitro-l-arginine methyl ester [l-NAME]) also prevented CRP-mediated O(2)(-) production further strengthening CRP-mediated eNOS uncoupling. Additionally, CRP decreased eNOS phosphorylation at Ser1177 as well as increased phosphorylation at Thr495. CRP appears to mediate these effects through the Fcgamma receptors, CD32 and CD64. To conclude, CRP uncouples eNOS resulting in increased superoxide production, decreased NO production and altered eNOS phosphorylation.

C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. Publishing Authors By Initials

U Singh,S Devaraj,J Vasquez-Vivar,I Jialal,U Singh,S Devaraj,J Vasquez-Vivar,I Jialal,U Singh,S Devaraj,J Vasquez-Vivar,I Jialal,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of molecular and cellular cardiology

VOLUME: 43

Page Numbers: 780-91

Journal Abbreviation: J. Mol. Cell. Cardiol.

ISSN: 0022-2828

DAY: 31

MONTH: 08

YEAR: 2007

C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 262322

C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.

AFFILIATION: Laboratory for Atherosclerosis and Metabolic Research, UC Davis Medical Center, University of California-Davis, 4635 2nd Avenue, Sacramento, CA 95817, USA.

Country: England

AGENCY: United States NHLBI

GRANT: R01 HL 074360

ACRONYM:

MEDLINETA: J Mol Cell Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling Related Publications

• A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress.
• Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop.
• C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.
• CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers.
• Contemporary scientific insights: role of biomarkers of inflammation in cardiovascular disease/atherosclerosis.
• Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results.
• Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome.
• Editor's Perspective on Metabolic Syndrome for 2008.
• Editorial.
• Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease.
• Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome.
• High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy.
• High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome.
• Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats.
• Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State.
• Oxidative stress and atherosclerosis.
• RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.
• Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome.
• Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
• Statins and biomarkers of inflammation.
• The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells.
• The effect of weight loss and dietary fatty acids on inflammation.
• Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity.